These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 19154961)

  • 1. Oxalic acid excretion after intravenous ascorbic acid administration.
    Robitaille L; Mamer OA; Miller WH; Levine M; Assouline S; Melnychuk D; Rousseau C; Hoffer LJ
    Metabolism; 2009 Feb; 58(2):263-9. PubMed ID: 19154961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ascorbic acid in idiopathic recurrent calcium urolithiasis in humans--does it have an abettor role in oxalate, and calcium oxalate crystallization?
    Schwille PO; Schmiedl A; Herrmann U; Manoharan M; Fan J; Sharma V; Gottlieb D
    Urol Res; 2000 Jun; 28(3):167-77. PubMed ID: 10929425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of large intake of ascorbic acid on urinary and plasma oxalic acid levels.
    Tsao CS; Salimi SL
    Int J Vitam Nutr Res; 1984; 54(2-3):245-9. PubMed ID: 6500850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative hyperoxaluria, crystalluria and haematuria after megadose ingestion of vitamin C.
    Auer BL; Auer D; Rodgers AL
    Eur J Clin Invest; 1998 Sep; 28(9):695-700. PubMed ID: 9767367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of vitamin C supplements on urinary oxalate and pH in calcium stone-forming patients.
    Baxmann AC; De O G Mendonça C; Heilberg IP
    Kidney Int; 2003 Mar; 63(3):1066-71. PubMed ID: 12631089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Excretion of 4-pyridoxic acid and oxalic acid in patients with urinary calculi.
    Tiselius HG
    Invest Urol; 1977 Jul; 15(1):5-8. PubMed ID: 873737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of water and sodium diuresis and furosemide on urinary excretion of vitamin B(6), oxalic acid and vitamin C in chronic renal failure.
    Mydlík M; Derzsiová K; Zemberová E
    Miner Electrolyte Metab; 1999; 25(4-6):352-6. PubMed ID: 10681666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Personal experiences in the long-term treatment of cystine lithiasis with high-dose ascorbic acid].
    Brundig P; Börner R; Berg W
    Z Urol Nephrol; 1982 Nov; 75(11):759-70. PubMed ID: 7164603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simple tests to determine urinary risk factors and calcium oxalate crystallization in the outpatient clinic.
    Kohri K; Kodama M; Ishikawa Y; Katayama Y; Kataoka K; Iguchi M; Yachiku S; Kurita T
    J Urol; 1991 Jul; 146(1):108-12. PubMed ID: 2056567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I clinical trial of i.v. ascorbic acid in advanced malignancy.
    Hoffer LJ; Levine M; Assouline S; Melnychuk D; Padayatty SJ; Rosadiuk K; Rousseau C; Robitaille L; Miller WH
    Ann Oncol; 2008 Nov; 19(11):1969-74. PubMed ID: 18544557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary oxalic acid excretion differs after oral loading of rats with various oxalate salts.
    Hossain RZ; Ogawa Y; Morozumi M; Sugaya K; Hatano T
    Int J Urol; 2003 Jan; 10(1):43-8. PubMed ID: 12534926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transient hyperoxaluria after ingestion of chocolate as a high risk factor for calcium oxalate calculi.
    Balcke P; Zazgornik J; Sunder-Plassmann G; Kiss A; Hauser AC; Gremmel F; Derfler K; Stockenhuber F; Schmidt P
    Nephron; 1989; 51(1):32-4. PubMed ID: 2915754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of ascorbic acid ingestion on the biochemical and physicochemical risk factors associated with calcium oxalate kidney stone formation.
    Auer BL; Auer D; Rodgers AL
    Clin Chem Lab Med; 1998 Mar; 36(3):143-7. PubMed ID: 9589801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Control of urinary risk factors of stones by betulin and lupeol in experimental hyperoxaluria.
    Vidya L; Varalakshmi P
    Fitoterapia; 2000 Sep; 71(5):535-43. PubMed ID: 11449502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetics of high-dose intravenous ascorbic acid in patients with advanced cancer.
    Stephenson CM; Levin RD; Spector T; Lis CG
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):139-46. PubMed ID: 23670640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose intravenous vitamin C combined with cytotoxic chemotherapy in patients with advanced cancer: a phase I-II clinical trial.
    Hoffer LJ; Robitaille L; Zakarian R; Melnychuk D; Kavan P; Agulnik J; Cohen V; Small D; Miller WH
    PLoS One; 2015; 10(4):e0120228. PubMed ID: 25848948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The determination of urinary oxalate by gas chromatography.
    Yanagawa M; Ohkawa H; Tada S
    J Urol; 1983 Jun; 129(6):1163-5. PubMed ID: 6854791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ascorbic acid overdosing: a risk factor for calcium oxalate nephrolithiasis.
    Urivetzky M; Kessaris D; Smith AD
    J Urol; 1992 May; 147(5):1215-8. PubMed ID: 1569652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcium oxalate stone formation risk - a case of disturbed relative concentrations of urinary components.
    Laube N; Rodgers A; Allie-Hamdulay S; Straub M
    Clin Chem Lab Med; 2008; 46(8):1134-9. PubMed ID: 18578688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The effect of furosemide on urinary excretion of oxalic acid, vitamin C and vitamin B6 in chronic kidney failure].
    Mydlík M; Derzsiová K; Zemberová E; Rajnic A
    Vnitr Lek; 1998 Mar; 44(3):127-31. PubMed ID: 9820088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.